Am J Transplant, Volume 18, Suppl 3 Archives - Page 10 of 211 - ATC Abstracts

2018 American Transplant Congress
AMD3100 (Plerixafor) as a Single-Dose Stem Cell Mobilizing Agent in Vascularized Composite Tissue Allograft (VCA) Transplantation in a Canine Model
B. Swearingen,^1,2 S. Graves,^2,3 R. Storb,^2,3 D. Mathes.^1,2
¹Surgery; Division of Plastic and Reconstructive Surgery, University of Colorado School of Medicine, Aurora, CO; ²Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; ³Medicine, University of Washington Medical Center, Seattle, WA.
PURPOSE:Vascularized Composite Allograft (VCA) transplantation is a clinical reality but limited by chronic immunosuppression and rejection. Current clinical tolerance protocols rely on recipient conditioning and…
2018 American Transplant Congress
Role of Calcium/Calmodulin Kinase IV on Podocyte Function in Transplant Glomerulopathy
R. Bhargava, K. Maeda, A. Ferreti, M. Pavlakis, G. Tsokos.
Beth Israel Deaconess Medical Center, Boston.
Background : Transplant glomerulopathy(TG) a histological manifestation of chronic antibody mediated rejection and a major cause of late allograft loss. It is well accepted that…
2018 American Transplant Congress
Functional Fc Gamma Receptor Gene Polymorphisms and Donor-Specific Antibody-Triggered Transplant Injury
M-.L. Arnold,¹ A. Kainz,² F. Eskandary,² N. Kozakowski,³ M. Wahrmann,² H. Haslacher,⁴ R. Oberbauer,² A. Heilos,⁵ B. Spriewald,⁶ L. Hidalgo,⁷ P. Halloran,⁸ G. Bohmig.²
¹Department of Internal Medicine 3, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; ²Department of Medicine III, Medical University of Vienna, Vienna, Austria; ³Department of Pathology, Medical University of Vienna, Vienna, Austria; ⁴Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria; ⁵Department of Paediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria; ⁶Department of Internal Medicine 5, Friedrich-Alexander University, Erlangen-Nuremberg, Germany; ⁷Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada; ⁸Alberta Transplant Applied Genomics Centre, ATAGC, University of Alberta, Edmonton, AB, Canada.
Fc-dependent effector mechanisms may play an important role in antibody-mediated rejection (ABMR). Distinct gene polymorphisms may determine the function of Fc gamma receptors (FcγR), potentially…
2018 American Transplant Congress
Exploring the Viability of Kidneys Discarded in the US: A Comparison of Kidney Utilization Patterns and Outcomes in the US and France
O. Aubert, P. Reese, M. Raynaud, D. Viglietti, C. Loheac, N. Kamar, M. Delahousse, C. Legendre, D. Glotz, C. Lefaucheur, A. Loupy.
Paris Translational Center for Organ Transplantation, Paris, France.
Approximately 2,000 donated kidneys are discarded in the US each year. Some transplant leaders have questioned the viability of these lost organs, while others suggest…
2018 American Transplant Congress
National Outcomes of Donor and Recipient Sex Mismatch in Kidney Transplantation
J. Buggs,¹ L. Wang,³ R. Liu,³ E. Rogers,² V. Bowers.¹
¹Transplant Surgery, Tampa General Medical Group, Tampa General Hospital, Tampa, FL; ²Transplant Research, Tampa General Hospital, Tampa, FL; ³Molecular Pharmacology & Physiology, University of South Florida, Tampa, FL.
Introduction: Gender Outcomes remain controversial in solid organ transplantation.Aim: The study aim was to evaluate the outcomes of sex mismatched donors and recipients where a…
2018 American Transplant Congress
MeltDose Prolonged-Release Once-Daily Tacrolimus (LCPT) vs. Conventional Tacrolimus Formulations in the Initial Maintenance of De Novo Kideny Transplant Recipients across Europe: STEADY Study
K. Budde,¹ G. Piotti,² C. Procaccianti,³ G. Nicolini,³ S. Geraci,³ D. Surace.³
¹Charité Universitatsmedizin, Berlin, Germany; ²Azienda Ospedaliero-Universitaria di Parma, Parma, Italy; ³Chiesi Farmaceutici S.p.A., Parma, Italy.
Tacrolimus is an immunosuppressant drug available as a twice-daily formulation (Prograf®, IR-Tac), or as once-daily formulations (Advagraf®, PR-Tac; Envarsus®, LCPT). LCPT has shown clinical non-inferiority…
2018 American Transplant Congress
Impact of Steroid Maintenance on the Outcomes of HLA-DR Mismatch Kidney Transplantation
B. Chopra, K. Sureshkumar.
Allegheny General Hospital, Pittsburgh, PA.
In kidney transplantation, donor-recipient HLA-DR mismatch poses high immunologic risk and is associated with inferior outcomes. We aimed to explore the impact of enhanced immunosuppression…
2018 American Transplant Congress
Can We Optimise Immunosuppression Strategies in Our Older Renal Transplant Recipients?
M. Morton,¹ K. Parker,¹ C. Morecroft.²
¹Manchester University Foundation Trust, Manchester, United Kingdom; ²Liverpool John Moores University, Liverpool, United Kingdom.
Renal transplantation provides a survival advantage for patients including those with multiple co-morbidities and older age compared to remaining on dialysis. The optimal immunosuppressive regime…
2018 American Transplant Congress
Opting out and Offers of 'Alibis' for Potential Living Kidney Donors in the US
R. Iskander,¹ S. Kulkarni,² C. Thiessen.²
¹McMaster University, Hamilton, ON, Canada; ²Yale University School of Medicine, New Haven, CT.
Purpose: To delineate rates of and reasons for opting out of living kidney donation, to determine if and how transplant centers offer alibis, to assess…
2018 American Transplant Congress
Chronic Changes on Time Zero Living Donor Allograft Biopsy Portraits Worse Donor Renal Function
A. Nishio-Lucar,¹ J. Murphy,² A. Sites,³ H. Cathro,² A. Doyle,¹ K. Warburton,¹ A. Agarwal.⁴
¹Medicine, University of Virginia, Charlottesville, VA; ²Pathology, University of Virginia, Charlottesville, VA; ³Transplant Services, University of Virginia, Charlottesville, VA; ⁴Surgery, University of Virginia, Charlottesville, VA.
The prognostic ability of zero hour biopsy (ZHB) in renal allografts has not been fully elucidated. ZHB utility predicting living kidney donor (LKD) renal recovery…